---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-024675"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T01:03:36.142272+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q2 revenue $542.7M on Sarepta deal; plozasiran PDUFA Nov 18, 2025

## Summary
- Q2 revenue of $542.7M (vs $0 prior year) driven by $825M Sarepta licensing deal ($500M cash + $325M equity).
- GAAP diluted EPS $2.75 vs ($1.02) loss YoY; net income $370.4M.
- FDA accepted plozasiran NDA for FCS with PDUFA date Nov 18, 2025; no advisory committee planned.
- CFO Ken Myszkowski retiring May 13, 2025; succeeded by Daniel Apel.
- Cash and investments $1.097B; company funded into 2028 with no near-term equity needs.

## SEC filing metadata
- accession: 0001628280-25-024675
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828025024675/0001628280-25-024675-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828025024675/arwr-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-024675
- JSON: https://secwatch.observer/filing/0001628280-25-024675.json
- Plain text: https://secwatch.observer/filing/0001628280-25-024675.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.